Corvus Pharmaceuticals (NASDAQ:CRVS) Earns “Neutral” Rating from Mizuho

Mizuho reiterated their neutral rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a $3.50 price objective on the stock.

Separately, Oppenheimer dropped their price target on Corvus Pharmaceuticals from $8.00 to $7.00 and set an outperform rating on the stock in a research report on Wednesday, March 20th.

Corvus Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ CRVS opened at $1.78 on Wednesday. Corvus Pharmaceuticals has a 12 month low of $0.66 and a 12 month high of $4.19. The company has a market cap of $87.29 million, a price-to-earnings ratio of -3.12 and a beta of 1.04. The business has a fifty day simple moving average of $2.08 and a 200-day simple moving average of $1.75.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its position in Corvus Pharmaceuticals by 63.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 20,543 shares of the company’s stock worth $47,000 after purchasing an additional 7,946 shares during the last quarter. State Street Corp increased its position in Corvus Pharmaceuticals by 12.2% in the 1st quarter. State Street Corp now owns 112,603 shares of the company’s stock worth $185,000 after purchasing an additional 12,203 shares during the last quarter. Renaissance Technologies LLC increased its position in Corvus Pharmaceuticals by 1.3% in the 3rd quarter. Renaissance Technologies LLC now owns 975,519 shares of the company’s stock worth $798,000 after purchasing an additional 12,587 shares during the last quarter. Tucker Asset Management LLC acquired a new position in Corvus Pharmaceuticals in the 2nd quarter worth about $29,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Corvus Pharmaceuticals in the 2nd quarter worth about $36,000. 46.64% of the stock is owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers.